Oregon Osteoporosis Center
Endocrinology
Dr. Michael R. McClung, MD
|
|
Give Review
Dr. Michael R. McClung practices Endocrinology. He went to medical school at University of Texas Southwestern Medical School. He received awards:"Portland Monthly Magazine" and "Fellow (FACP)". Michael McClung is a published doctor and has 58 publications published. The lastest was: 'Vertebral fractures: clinical importance and management.' He accepts Medicare.
Publications
- Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacat...
- New management options for osteoporosis with emphasis on SERMs.
- Vertebral fractures: clinical importance and management.
- Overdiagnosis and Overtreatment of Osteoporosis: A Wolf in Sheep's Clothing.
- Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture ...
- Bone safety with risedronate: histomorphometric studies at different dose levels and exposure.
- Creation of an Age-Adjusted, Dual-Energy X-ray Absorptiometry-Derived Trabecular Bone Score Curve for the Lumbar Spine in Non-Hispanic US White Women.
- Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.
- Romosozumab in Postmenopausal Women with Low Bone Mineral Density.
- Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
- Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis.
- Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study.
- Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.
- Osteoporosis Update From the 2012 Santa Fe Bone Symposium.
- Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
- Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
- In memoriam: sergio ragi-eis, MD.
- Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.
- A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data.
- Revisiting the prevention of bone loss at menopause.
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.
- Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
- A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density.
- To FRAX or not to FRAX.
- Femoral strength in osteoporotic women treated with teriparatide or alendronate.
- Effects of denosumab on fracture and bone mineral density by level of kidney function.
- Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
- Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
- Osteoporosis update from the 2010 santa fe bone symposium.
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive su...
- Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
- Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond.
- Postmenopausal osteoporosis: fracture risk and prevention.
- Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
- Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
- Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
- Looking for answers in all the wrong places.
- Bisphosphonates and osteonecrosis of the jaw.
- Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.
- Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
- Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies.
- Do current management strategies and guidelines adequately address fracture risk?
- Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
- Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
- Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
- The relationship between bone mineral density and fracture risk.
- Osteopenia: to treat or not to treat?
- Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and ...
- Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment.
- Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures.
- Bisphosphonates.
- Pathogenesis of osteoporotic hip fractures.
- How does raloxifene reduce fracture risk?
- Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study.
- Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.
- A national random survey of bone mineral density reporting in the United States.
Schools
University of Texas Southwestern Medical Center At Dallas
Parkland Memorial Hospital
National Institute Health
Doctors Specialties
- Other
- Endocrinology
Accepted Insurances
Awards
- Portland Monthly Magazine
- Fellow (FACP)
Education
-
University of Texas Southwestern Medical School
Hospital
-
Providence Portland Medical Center
Drug Facts
| NPI NUMBER | 1477580207 | |
| NPPES Provider LastName | MCCLUNG | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 972132991 | |
| NPPES Provider State | OR | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 161.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1477580207 |
| Last Name Of The Provider | MCCLUNG |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Paul B. Duell, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barbara D. Hettinger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald L. Loriaux, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Teresa A. Hillier, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Joseph S. Mallov, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Clayton C. Kammer, CADC |